Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | GPR183 | P32249 | 3/20 | 0.42 |
| ▸ | TGM2 | P21980 | 3/20 | 0.42 |
| ▸ | F13A1 | P00488 | 2/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197981 | 1.00 | F10 (0.55) | F10F2GPR183TGM2F13A1 | |
| SCHEMBL6198242 | 0.86 | F10 (0.74) | F10F2 | |
| SCHEMBL6197070 | 0.84 | F10 (0.55) | F10F2TGM2F13A1TGM1 | |
| SCHEMBL6195846 | 0.83 | F10 (0.55) | F10F2TGM2F13A1 | |
| SCHEMBL6196084 | 0.83 | F10 (0.70) | F10F2 | |
| SCHEMBL6197249 | 0.83 | F10 (0.54) | F10F2 | |
| SCHEMBL6194842 | 0.82 | F10 (0.54) | F10F2 | |
| SCHEMBL6730047 | 0.82 | F10 (0.53) | F10F2TGM2F13A1 | |
| SCHEMBL6198463 | 0.80 | F10 (0.53) | F10F2 | |
| SCHEMBL6737275 | 0.80 | F10 (0.72) | F10F2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1031563-B1 | SULFONYL DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | F10 19/4885F2 1/4885GPR183 4185/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | F10 76/4885F2 4/4885GPR183 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.